Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...